Type I interferon as a pre‐lupus marker in anti‐nuclear antibody‐associated childhood immune thrombocytopenic purpura

Le résumé fourni par la source

Paediatric-onset anti-nuclear antibody-associated immune thrombocytopenic purpura (ITP-ANA+) is a pre-lupus condition. Interferon signature (IS) is a reliable method to measure interferon-stimulated gene expression which is commonly raised in systemic lupus erythematosus (SLE) and in adult pre-lupus cases. Between 2022 and 2024, IS analysis was performed on 61 children, 17 with ITP-ANA+, 15 with ITP-ANA-, 15 with SLE and 14 with juvenile idiopathic arthritis. IS was positive in 14/17 children (82%), with a median score of 17 (1.2-143). This median IS was significantly higher than in the ITP-ANA- group (2.8, 1-41, p = 0.03) and lower than in the SLE group (37.5, 2.1-129, p = 0.04). Among ITP-ANA+ children, IS elevation was associated with age >10 years at ITP diagnosis, newly diagnosed or persistent ITP, positive anti-extractable nuclear antigen antibodies and the absence of hydroxychloroquine treatment. Hydroxychloroquine significantly reduced IS values in three children with pre- and post-treatment scores available. The involvement of type I interferon signalling in childhood ITP-ANA+ highlights a distinct pathogenic pathway and IS appears as a pertinent biomarker to identify patients at risk of progression to SLE. The introduction of hydroxychloroquine in these patients could help prevent the high morbidity of SLE at adult age.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.